Lv6
2600 积分 2022-06-29 加入
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
4天前
已完结
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
27天前
已完结
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
27天前
已完结
Gastric cancer
2个月前
已完结
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
3个月前
已完结
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non–MSI-H/non–dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results
3个月前
已完结
Claudin 18.2 as a novel therapeutic target
3个月前
已完结
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
4个月前
已完结
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
4个月前
已完结
Comparative efficacy and tolerability of first-line treatments for untreated, HER2-negative, advanced gastric cancer: systematic review and network meta-analysis
6个月前
已完结
皖公网安备34019202002308
